Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Chronic hepatitis B (CHB) is a serious liver disease caused by the failure of viral clearance following acute hepatitis B virus (HBV) infection. The global disease burden is high in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China); it is especially high in China. For most patients, CHB is a lifelong disease that cannot be cured, with only a very small number of patients entering remission each year. Patients with CHB have a 20% risk of developing life-threatening liver disease, such as cirrhosis and hepatocellular carcinoma (HCC) as a result of their condition. Guidelines by the American Association of the Study of Liver Diseases (AASLD) and the European Association for the Study of Liver (EASL) have recommended CHB to be treated with nucleotide analogs (NA).

Gilead Sciences and Bristol Myers Squibb (BMS) are the major players within the CHB market with their nucleotide analogs Viread (TDF, Gilead), Vemlidy (TAF, Gilead) and Baraclude (entecavir, BMS). However, generic versions of TDF and entecavir dominate the 9MM. The CHB treatment pipeline is predominantly in early stages. Gilead’s TLR-8 agonist selgantolimod, J&J’s capsid assembly modulator JNJ-6379, and antisense nucleotide JNJ-3898 could significantly impact the CHB market across the 9MM. Also Replicor, Assembly Biosciences, and Ionis Pharmaceuticals are developing CHB therapies. A major unmet for CHB treatment remains the potential to achieve functional cure.

Key Questions Answered

How will the CHB market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2019-2029?
What are the most promising late-stage pipeline products for CHB treatment?
How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing CHB treatment options?
What are the remaining unmet needs in CHB treatment?
What drivers and barriers will affect CHB treatment sales in the 9MM over the forecast period?

Scope

Overview of CHB, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline CHB treatment market revenue from 2019-2029. Annual cost of therapy and major pipeline product sales in this forecast period are included.

Key topics covered include current CHB treatment, unmet needs and opportunities, and the drivers and barriers affecting CHB treatment sales in the 9MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global CHB treatment market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

During the 10-year forecast period, there are six major pipeline products that are on track to launch, driving a forecast growth in the 9MM from $3.8B in 2019 to $5.2B in 2029, which represents a CAGR of 3.1%.

To combat the unmet need of a functional cure, companies such as Gilead, J&J, Replicor, Ionis, and Assembly Biosciences are developing pipeline products with novel mechanism of action, with the potential of being used as a combination therapy either with current nucleotide analogs or with emerging products. The pipeline products are expected to launch in the second half of the forecast period in 2029. Antisense nucleotides are expected to gain a market share of 14.7% and sales of $761M in the 9MM by 2029. However, capsid assembly modulators from J&J and a toll-like receptor 8 agonist from Gilead are expected to compete with antisense nucleotides for market shares in the 9MM by the end of the forecast period.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Hepatitis B Virus Infection market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis B Virus Infection market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Gilead Sciences
Johnson & Johnson
Assembly Biosciences
Ionis Pharmaceuticals/GlaxoSmithKline
Replicor
HEC Pharma
Ligand Pharmaceuticals
Jiangsu Hansoh Pharmaceutical Group
Bristol-Myers Squibb Co
GlaxoSmithKline
Merck & Co
F. Hoffmann-La Roche

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Chronic Hepatitis B: Executive Summary

1.1 Chronic Hepatitis B Treatment to Experience Modest Market Growth over the Forecast Period from 2019–2029

1.2 Hepatitis B Therapies with Novel MOAs Will Supplement Existing NA Treatment

1.3 Pipeline Therapies with Novel MOAs Are Aiming to Increase CHB Cure Rates

1.4 Current CHB Treatment Pipeline Includes Agents with Novel MOAs

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for CHB (2019–2029)

4.5.1 Diagnosed Prevalent Cases of CHB

4.5.2 Age-Specific Diagnosed Prevalent Cases of CHB

4.5.3 Sex-Specific Diagnosed Prevalent Cases of CHB

4.5.4 Diagnosed Prevalent Cases of CHB by HBeAg Status

4.5.5 Diagnosed Prevalent Cases of CHB by HBV DNA Level

4.5.6 Diagnosed Prevalent Cases of CHB by ALT Level

4.5.7 Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impacts

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.1.1 Treatment Guidelines and Leading Prescribed Drugs

5.1.2 Clinical Practice

5.2 KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 The Need for a Functional Cure

7.3 Reduction in Drug Administration

7.4 Reduction in Treatment Time Frame

7.5 Discovery of Biomarkers

7.6 Improve Access to Diagnostics

8 R&D Strategies

8.1 Overview

8.1.1 R&D Strategy 1 – Mechanism of Action

8.1.2 R&D Strategy 2 – Combination Therapy

8.1.3 R&D Strategy 3 – Company Partnerships

8.2 Clinical Trials Design

8.2.1 Clinical Trials Design – Primary Endpoints

8.2.2 Clinical Trials Design – Combination Therapies

8.2.3 Clinical Trials Design – Focused on Phase II

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Trends in Corporate Strategy

11.3 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 Brazil

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

12.6 China

12.6.1 Forecast

12.6.2 Key Events

12.6.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Global Director of Therapy Analysis and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Key Metrics for CHB in the 9MM

Table 2: Phases of CHB Infection

Table 3: Risk Factors and Comorbidities for Chronic Hepatitis B

Table 4: Treatment Guidelines for CHB

Table 5: Country Profile – US

Table 6: Country Profile – 5EU

Table 7: Country Profile – Japan

Table 8: Country Profile – Brazil

Table 9: Country Profile – China

Table 10: Chronic Hepatitis B Market – Global Drivers and Barriers, 2019–2029

Table 11: Key Events Impacting Sales for Chronic Hepatitis B Treatment in the US, 2019–2029

Table 12: Chronic Hepatitis B Market – Drivers and Barriers in the US, 2019–2029

Table 13: Key Events Impacting Sales for Chronic Hepatitis B Treatment in the 5EU, 2019–2029

Table 14: Chronic Hepatitis B Market – Drivers and Barriers in the 5EU, 2019–2029

Table 15: Key Events Impacting Sales for Chronic Hepatitis B Treatment in Japan, 2019–2029

Table 16: Chronic Hepatitis B Market – Drivers and Barriers in Japan, 2019–2029

Table 17: Key Events Impacting Sales for Chronic Hepatitis B Treatment in Brazil, 2019–2029

Table 18: Chronic Hepatitis B Market – Drivers and Barriers in Brazil, 2019–2029

Table 19: Key Events Impacting Sales for Chronic Hepatitis B Treatment in China, 2019–2029

Table 20: Chronic Hepatitis B Market – Drivers and Barriers in China, 2019–2029

Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for CHB in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in CHB During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of CHB During the Forecast Period

Figure 4: Hepatitis B Virus Structure

Figure 5: Key Steps in HBV Replication and Potential Therapeutic Targets

Figure 6: 9MM, Diagnosed Prevalence of CHB (%), Both Sexes, All Ages, 2009–2019.

Figure 7: 9MM, Sources Used and Not Used for Diagnosed Prevalence of CHB (%)

Figure 8: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by HBeAg Status (N)

Figure 9: 9MM, Sources Used and Not Used for Diagnosed Prevalent Cases of CHB by HBV DNA Level (N)

Figure 10: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by ALT Level (N)

Figure 11: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis (N)

Figure 12: 9MM, Diagnosed Prevalent Cases of CHB, Men and Women, All Ages, N, 2019

Figure 13: 9MM, Age-Specific Diagnosed Prevalent Cases of CHB, 9MM, Men and Women, All Ages, N, 2019

Figure 14: 9MM, Sex-Specific Diagnosed Prevalent Cases of CHB, All Ages, N, 2019

Figure 15: 9MM, Diagnosed Prevalent Cases of CHB by HBeAg Status, Men and Women, All Ages, N, 2019

Figure 16: 9MM, Diagnosed Prevalent Cases of CHB by HBV DNA Level, Men and Women, All Ages, N, 2019

Figure 17: 9MM, Diagnosed Prevalent Cases of CHB by ALT Level, Men and Women, All Ages, N, 2019

Figure 18: 9MM, Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis, Men and Women, All Ages, N, 2019

Figure 19: Unmet Needs and Opportunities in CHB

Figure 20: Overview of the Development Pipeline in Chronic Hepatitis B

Figure 21: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for CHB in the 9MM During the Forecast Period

Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of CHB During the Forecast Period

Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), entecavir, TDF, and TAF

Figure 24: Analysis of the Company Portfolio Gap in CHB During the Forecast Period

Figure 25: Global (9MM) Sales Forecast by Country for Chronic Hepatitis B in 2019 and 2029

Figure 26: Sales Forecast by Class for Chronic Hepatitis B in the US in 2019 and 2029

Figure 27: Sales Forecast by Class for Chronic Hepatitis B in the 5EU in 2019 and 2029

Figure 28: Sales Forecast by Class for Chronic Hepatitis B in Japan in 2019 and 2029

Figure 29: Sales Forecast by Class for Chronic Hepatitis B in Brazil in 2019 and 2029

Figure 30: Sales Forecast by Class for Chronic Hepatitis B in China in 2019 and 2029

Frequently asked questions

Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029 in real time.

  • Access a live Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.